These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries. Servín-Blanco R; Chávaro-Ortiz RM; Zamora-Alvarado R; Martínez-Cortes F; Gevorkian G; Manoutcharian K Immunol Lett; 2018 Dec; 204():47-54. PubMed ID: 30339819 [TBL] [Abstract][Full Text] [Related]
6. Generation of cancer vaccine immunogens derived from Oncofetal antigen (OFA/iLRP) using variable epitope libraries tested in an aggressive breast cancer model. Martínez-Cortés F; Servín-Blanco R; Domínguez-Romero AN; Munguía ME; Guzman Valle J; Odales J; Gevorkian G; Manoutcharian K Mol Immunol; 2021 Nov; 139():65-75. PubMed ID: 34454186 [TBL] [Abstract][Full Text] [Related]
7. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408 [TBL] [Abstract][Full Text] [Related]
8. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer. Singh R; Paterson Y Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378 [TBL] [Abstract][Full Text] [Related]
9. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. Rice J; Buchan S; Stevenson FK J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189 [TBL] [Abstract][Full Text] [Related]
10. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice. Kasamatsu J; Takahashi S; Azuma M; Matsumoto M; Morii-Sakai A; Imamura M; Teshima T; Takahashi A; Hirohashi Y; Torigoe T; Sato N; Seya T Immunobiology; 2015 Jan; 220(1):74-82. PubMed ID: 25257859 [TBL] [Abstract][Full Text] [Related]
12. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses. Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666 [TBL] [Abstract][Full Text] [Related]
14. Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice. Ghaffari-Nazari H; Tavakkol-Afshari J; Jaafari MR; Tahaghoghi-Hajghorbani S; Masoumi E; Jalali SA PLoS One; 2015; 10(11):e0142563. PubMed ID: 26556756 [TBL] [Abstract][Full Text] [Related]
15. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579 [TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer. Odales J; Servín-Blanco R; Martínez-Cortés F; Guzman Valle J; Domínguez-Romero AN; Gevorkian G; Manoutcharian K Vaccine; 2022 Aug; 40(33):4796-4805. PubMed ID: 35788294 [TBL] [Abstract][Full Text] [Related]
17. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire. Rice J; Buchan S; Dewchand H; Simpson E; Stevenson FK J Immunol; 2004 Oct; 173(7):4492-9. PubMed ID: 15383580 [TBL] [Abstract][Full Text] [Related]
18. Development of a novel T cell-oriented vaccine using CTL/Th-hybrid epitope long peptide and biodegradable microparticles, against an intracellular bacterium. Tanaka K; Enomoto N; Uehara M; Furuhashi K; Sakurai S; Yasui H; Karayama M; Hozumi H; Suzuki Y; Fujisawa T; Inui N; Nakamura Y; Nagata T; Suda T Microbiol Immunol; 2020 Oct; 64(10):666-678. PubMed ID: 32786043 [TBL] [Abstract][Full Text] [Related]
19. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody]. Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545 [TBL] [Abstract][Full Text] [Related]
20. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen. Shen H; Shao HW; Chen XH; Wu FL; Wang H; Huang ZL; Shen J; Wang T; Zhang WF; Huang SL Cancer Immunol Immunother; 2013 Feb; 62(2):393-403. PubMed ID: 22926105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]